U19NS130617

Harvard Precision Human Pain Center - Project Summary (Overall)

Chronic pain affects over 25 million Americans per year, with enormous impacts on both quality of life and productivity. Despite advances in our understanding of nociception in animal models, new and effective treatments for patients with chronic pain have been lacking. The poor translation between mouse and human pain targets has highlighted limitations of animal models of pain.

Recent advances in single-cell genomics and physiology directly in human tissue position pain researchers to make important new advances with improved opportunities for clinical translation. The Harvard Precision Human Pain Center proposes to leverage state-of-the-art single-cell technologies to characterize human nociceptor subtypes and how their gene expression patterns vary across diverse populations (Project 1). Additionally, the center aims to study chronic pain conditions that clearly localize to these cells, such as chronic phantom limb pain associated with painful neuromas (Project 2).

The projects will generate a wealth of data for the scientific community by closely integrating with five cores tasked with the following:

1) Procuring high-quality human pain-related tissues following strict regulatory practices,
2) Offering the latest single-cell gene multi-omic technologies,
3) Performing advanced single-cell spatial transcriptomic analysis,
4) Managing, integrating, and distributing all of the data, and
5) Administering and connecting to the other Precision Human Pain Network centers.

The data generated by our center will contribute to this broader Precision Human Pain Network and help identify and prioritize novel pain therapeutic targets for future investigation.

Brigham & Womens Hospital

TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.279 - Drug Abuse and Addiction Research Programs

National Institute of Neurological Disorders and Stroke (NNDS) [HHS - NIH]

Boston, Massachusetts 021156110 United States

Single Zip Code

HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes and Cells (U19 Clinical Trial Not Allowed) (RFA-NS-22-018)

Amendment Since initial award the total obligations have increased 292% from $2,647,394 to $10,370,611.